Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.

Key facts

Sponsor

Aparna Goel

Principal Investigator

Aparna Goel, MD

Stanford University

Intervention

Hymecromone(drug)

Enrollment

24 enrolled

Eligibility

14-75 years · All sexes

Timeline

2023 – 2027

Study locations (2)

• Stanford Clinic, Redwood City, California, United States
• Stanford Clinic, Stanford, California, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Primary sclerosing cholangitis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07229911
  A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)
  Takeda
• RECRUITINGPHASE2NCT06699121
  A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC
  LISCure Biosciences
• RECRUITINGPHASE2NCT06905054
  Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
  Mayo Clinic
• RECRUITINGNANCT06865924
  Colangioids to Define the Genetic Factors Involved in Atypical Primary Sclerosing Cholangitis
  Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
• RECRUITINGNCT06297993
  Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC Study)
  PSC Partners Seeking a Cure
• RECRUITINGNANCT06351696
  The Effects of Bromelain Supplement in Patients With Ulcerative Colitis
  National Nutrition and Food Technology Institute
• RECRUITINGPHASE2NCT06286709
  FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis
  University of Birmingham
• RECRUITINGEARLY PHASE1NCT06197308
  Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC
  University of Minnesota

See all trials for Primary sclerosing cholangitis →